TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28826229

Group type: COMPARATOR
Intervention: Provider-administered rapid blood (finger-prick) HIV test (standard of care)
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Choice between SOC or a self-administered oral rapid HIV test with provider supervision
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Choice with option to take an HIV test kit for home use
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Choice arm participants who tested
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Offering a test kit for home use to those who refused testing in the clinic
Number of subjects: 305
Study: 27618967

Group type: EXPERIMENTAL
Intervention: Bilateral pudendal nerve block with 0.33% ropivacaine
Number of subjects: 94

Group type: COMPARATOR
Intervention: Intravenous tramadol 1.5 mg/kg
Number of subjects: 94
Study: 23888359

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 or 12 international units depending on weight)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Intranasal placebo
Number of subjects: 38
Study: 23800312

Group type: EXPERIMENTAL
Intervention: Levofloxacin 500 mg po daily for 3 months
Number of subjects: 154

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study: 20885202

Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) treatment at frequencies of 30, 35, 40, or 50 Hz and amplitudes of 2-4 or 4-6 mm for 1 minute.
Number of subjects: 90

Group type: COMPARATOR
Intervention: Nonvibration control group
Number of subjects: 90
Study: 17900393

Group type: EXPERIMENTAL
Intervention: Group CBT (Cognitive Behavioral Therapy) targeting reduction of distress associated with hallucinations
Number of subjects: 63

Group type: COMPARATOR
Intervention: Group ST (Supportive Therapy) focusing on improving social integration
Number of subjects: 63
Study: 16897271

Group type: EXPERIMENTAL
Intervention: Adjuvant intraportal infusion chemotherapy (IPIC) with 5-fluorouracil (650 mg/m²), leucovorin (45 mg/m²), doxorubicin (10 mg/m²), and cisplatin (20 mg/m²) for 6 cycles, starting 5 to 24 days after surgery.
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Adjuvant intraportal infusion chemotherapy (IPIC) for patients with stage I and II disease.
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (hepatectomy without adjuvant therapy).
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (hepatectomy without adjuvant therapy) for patients with stage I and II disease.
Number of subjects: 28
Study: 14498765

Group type: EXPERIMENTAL
Intervention: Ribosomal immunostimulant (Ribomunyl®)
Number of subjects: 2117

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2117
Study: 10757152

Group type: EXPERIMENTAL
Intervention: Group B (1 g magnesium sulfate in pump prime plus 5 mmol/L in cardioplegic solution)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Group C (5 mmol/L in cardioplegic solution)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Group A (1 g magnesium sulfate added to pump prime)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Group D (placebo control)
Number of subjects: 97
Study: 8640047

Group type: EXPERIMENTAL
Intervention: 0.25 mg b.i.d. nebulized budesonide
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: 1 mg b.i.d. nebulized budesonide
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo stage (control group)
Number of subjects: 102
Study: 1505648

Group type: EXPERIMENTAL
Intervention: Gemfibrozil (G)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pravastatin
Number of subjects: 0
Study: 6219089

Group type: EXPERIMENTAL
Intervention: Cefoperazone
Number of subjects: 113

Group type: COMPARATOR
Intervention: Cefamandole
Number of subjects: 113
Study: 29672817

Group type: EXPERIMENTAL
Intervention: Intrapleural instillation of 50 mL autologous blood 3 days after insertion of chest drain (Group A)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Conservative management (Group B)
Number of subjects: 47
Study: 30419875

Group type: EXPERIMENTAL
Intervention: Supportive-expressive psychotherapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Supportive psychotherapy
Number of subjects: 100
Study: 27103127

Group type: EXPERIMENTAL
Intervention: Romiplostim
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 25483677

Group type: EXPERIMENTAL
Intervention: Tecemotide (L-BLP25)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Single or multiple low doses of cyclophosphamide
Number of subjects: 34
Study: 22743596

Group type: EXPERIMENTAL
Intervention: Raltegravir (400 mg bid)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Efavirenz
Number of subjects: 160
Study: 19667251

Group type: EXPERIMENTAL
Intervention: olmesartan/azelnidipine (20.0 mg and 16.0 mg)
Number of subjects: 207

Group type: COMPARATOR
Intervention: olmesartan/hydrochlorothiazide (20.0 mg and 12.5 mg)
Number of subjects: 207
Study: 17475737

Group type: EXPERIMENTAL
Intervention: CBT
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: venlafaxine
Number of subjects: 24
Study: 15851259

Group type: EXPERIMENTAL
Intervention: Rate control (n = 160)
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Rhythm control (n = 175)
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Rhythm control (sinus rhythm at study end)
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Atrial fibrillation at study end
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Hypertension and no use of angiotensin-converting enzyme inhibitors
Number of subjects: 335
Study: 12386569

Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP) levels
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Troponin T (TnT) levels
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Left atrial diameter
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Left ventricular end-diastolic diameter (LVEDD) and ejection fraction (EF)
Number of subjects: 15
Study: 9537210

Group type: EXPERIMENTAL
Intervention: SK&F107647 at 0.01 ng/kg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: SK&F107647 at 0.1 ng/kg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: SK&F107647 at 1.0 ng/kg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: SK&F107647 (dose range 0.01 to 100 ng/kg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: SK&F107647
Number of subjects: 16
Study: 7699836

Group type: EXPERIMENTAL
Intervention: SY5555 5 mg/kg
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: SY5555 10 mg/kg
Number of subjects: 22
Study: 2679037

Group type: EXPERIMENTAL
Intervention: 25 g carbohydrate as potato
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 25 g carbohydrate as spaghetti
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 25 g protein added to both meals
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 25 g protein and 25 g fat added to mashed potato
Number of subjects: 6
Study: 334216

Group type: EXPERIMENTAL
Intervention: Nomifensine 75 mg alone
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Clobazam 15 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Clobazam 30 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nomifensine 75 mg with Clobazam 15 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nomifensine 75 mg with Clobazam 30 mg
Number of subjects: 10
Study: 31481069

Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 14671

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14671
Study: 28063876

Group type: EXPERIMENTAL
Intervention: Breakfast (at least 15% of daily energy requirement before 8:30 a.m.)
Number of subjects: 49

Group type: COMPARATOR
Intervention: No breakfast (no energy until after 11:30 a.m.)
Number of subjects: 49
Study: 25997686

Group type: EXPERIMENTAL
Intervention: Enhanced Recovery After Surgery (ERAS)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 86
Study: 23870702

Group type: EXPERIMENTAL
Intervention: Prediction model for relaparotomy decision-making
Number of subjects: 182
Study: 22127708

Group type: EXPERIMENTAL
Intervention: 10 mg/kg belimumab plus standard therapy
Number of subjects: 819

Group type: EXPERIMENTAL
Intervention: 1 mg/kg belimumab plus standard therapy
Number of subjects: 819

Group type: COMPARATOR
Intervention: Placebo plus standard therapy
Number of subjects: 819

Group type: EXPERIMENTAL
Intervention: 1 mg/kg belimumab
Number of subjects: 819

Group type: EXPERIMENTAL
Intervention: 10 mg/kg belimumab
Number of subjects: 819

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 819
Study: 19567505

Group type: EXPERIMENTAL
Intervention: Prostate-specific antigen test
Number of subjects: 39389
Study: 17908055

Group type: EXPERIMENTAL
Intervention: Concomitant vaccination with ZOSTAVAX and inactivated influenza vaccine
Number of subjects: 762

Group type: COMPARATOR
Intervention: Sequential vaccination with ZOSTAVAX and inactivated influenza vaccine
Number of subjects: 762

Group type: EXPERIMENTAL
Intervention: Concomitant vaccination
Number of subjects: 762

Group type: COMPARATOR
Intervention: Sequential vaccination
Number of subjects: 762
Study: 15516645

Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine and albendazole therapy (DEC/ALB)
Number of subjects: 58
Study: 11600924

Group type: EXPERIMENTAL
Intervention: Intervention group (exercise program with ergonomic education, administered twice a week for four months)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 9783495

Group type: EXPERIMENTAL
Intervention: Older hypertensive patients (OHT)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Older normotensive patients (OHS)
Number of subjects: 46
Study: 7824594

Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3135204

Group type: EXPERIMENTAL
Intervention: 15 mg of slow-release terbutaline
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 31219027

Group type: EXPERIMENTAL
Intervention: HPV testing (revealed arm)
Number of subjects: 24496

Group type: COMPARATOR
Intervention: Cytology (concealed arm)
Number of subjects: 24496

Group type: EXPERIMENTAL
Intervention: New HPV infection at round 2
Number of subjects: 24496

Group type: EXPERIMENTAL
Intervention: Type-specific persistent infections
Number of subjects: 24496

Group type: EXPERIMENTAL
Intervention: HPV infection with normal cytology
Number of subjects: 24496

Group type: EXPERIMENTAL
Intervention: Persistent HPV infections
Number of subjects: 24496
Study: 28699417

Group type: EXPERIMENTAL
Intervention: MoM (Metasul)
Number of subjects: 30

Group type: COMPARATOR
Intervention: MoP (Protasul)
Number of subjects: 30
Study: 25046578

Group type: EXPERIMENTAL
Intervention: Narrative writing intervention
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Comparison between groups
Number of subjects: 70
Study: 23639625

Group type: EXPERIMENTAL
Intervention: $30 Australian Dollars cash following receipt of vaccine doses two and three
Number of subjects: 139

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 139
Study: 21518554

Group type: EXPERIMENTAL
Intervention: Alemtuzumab (15 mg) as a single dose before reperfusion and another 15 mg at 24 hours post-operation
Number of subjects: 23

Group type: COMPARATOR
Intervention: Anti-thymocyte globulin (ATG) (9 mg/kg) given 2 hours before kidney transplantation
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Number of subjects: 23

Group type: COMPARATOR
Intervention: Anti-thymocyte globulin (ATG)
Number of subjects: 23

Group type: COMPARATOR
Intervention: ATG
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 23
Study: 18676038

Group type: EXPERIMENTAL
Intervention: 6-month exercise-based Cardiac Rehabilitation (CR) program
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study: 16740113

Group type: EXPERIMENTAL
Intervention: Psychopathic violent offenders (P-VO)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonpsychopathic violent offenders (NP-VO)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Violent offenders (VO)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Psychopathy
Number of subjects: 0
Study: 14594020

Group type: EXPERIMENTAL
Intervention: Subcutaneous enfuvirtide added to an optimized oral background antiretroviral regimen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Optimized oral background antiretroviral regimen
Number of subjects: 0
Study: 10880321

Group type: EXPERIMENTAL
Intervention: Various therapies administered to patients
Number of subjects: 124
Study: 8883925

Group type: EXPERIMENTAL
Intervention: Language stimuli (bisyllablic content words)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Non-language stimuli (physically similar non-language stimuli)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Language stimuli (auditory condition)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Non-language stimuli (visual condition)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Language and non-language stimuli
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Language stimuli
Number of subjects: 12
Study: 1548251

Group type: EXPERIMENTAL
Intervention: Desipramine
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Desipramine and Placebo
Number of subjects: 83
Study: 3856578

Group type: EXPERIMENTAL
Intervention: Test group (T) received prophylaxes according to a previously described schedule and based on DDFM test outcome. Recall intervals ranged from 1 to 24 months (mean: 15.7 months).
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control group (C) received regular prophylaxes every 6 months.
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Test group (T) and Control group (C)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Test group (T)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Both groups (C and T)
Number of subjects: 69
Study: 29486796

Group type: EXPERIMENTAL
Intervention: Deworming treatment
Number of subjects: 0
Study: 27650605

Group type: EXPERIMENTAL
Intervention: High-quality protein supplementation
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Low-quality protein supplementation
Number of subjects: 12
Study: 24858376

Group type: EXPERIMENTAL
Intervention: 2 g TRP-rich protein hydrolysate
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 4 g TRP-rich protein hydrolysate
Number of subjects: 60

Group type: COMPARATOR
Intervention: 3.11 g casein hydrolysate
Number of subjects: 60
Study: 22391955

Group type: EXPERIMENTAL
Intervention: High-voltage electrical stimulation (HVES) at 100 V, 100 μs, 100 Hz for 50 minutes once daily, five times per week
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard supportive care and topical treatments with wet-to-moist dressings
Number of subjects: 50
Study: 20718163

Group type: EXPERIMENTAL
Intervention: Liquid simethicone (2 ml in 60 ml of water)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study: 17914010

Group type: EXPERIMENTAL
Intervention: Theory of planned behavior guided class
Number of subjects: 94

Group type: COMPARATOR
Intervention: Standard continuing education class
Number of subjects: 94
Study: 15948782

Group type: EXPERIMENTAL
Intervention: 3.2‐mm arched blade
Number of subjects: 74

Group type: COMPARATOR
Intervention: 3.2‐mm flat blade
Number of subjects: 74
Study: 12351481

Group type: EXPERIMENTAL
Intervention: Insulin infusion (10 IU of regular insulin)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Saline alone (50 ml saline)
Number of subjects: 19
Study: 10493689

Group type: EXPERIMENTAL
Intervention: Systemic JRA
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Oligo and polyarticular JRA
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control
Number of subjects: 33
Study: 9026952

Group type: EXPERIMENTAL
Intervention: Depakin syrup (initial dose 300 mg/day, increased to 1200 mg/day)
Number of subjects: 11
Study: 1788755

Group type: EXPERIMENTAL
Intervention: 0.2 ng PGE 1/kg body weight/min and 15,000 i.U. of heparine continuously
Number of subjects: 133

Group type: COMPARATOR
Intervention: 15,000 i.U. of heparine and 3 x 0.5 g of Aspirin
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: 60 micrograms PGE 1 in 250 ml saline twice daily
Number of subjects: 133

Group type: COMPARATOR
Intervention: 250 ml saline twice over a period of three weeks
Number of subjects: 133
Study: 7212227

Group type: EXPERIMENTAL
Intervention: Halothane 0.4%, nitrous oxide 33%, oxygen 66%
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nitrous oxide and oxygen ratio reversed for the first 3 minutes
Number of subjects: 20
Study: 31069833

Group type: EXPERIMENTAL
Intervention: Er:YAG laser (100 mJ/pulse; 15 Hz to hard tissue and 50 mJ/pulse; 30 Hz to soft tissue) plus SRP
Number of subjects: 27

Group type: COMPARATOR
Intervention: SRP only
Number of subjects: 27
Study: 30052229

Group type: EXPERIMENTAL
Intervention: TEA (Group A)
Number of subjects: 50

Group type: COMPARATOR
Intervention: ESP block (Group B)
Number of subjects: 50
Study: 26876224

Group type: EXPERIMENTAL
Intervention: Alpha BRAIN®
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 25073836

Group type: EXPERIMENTAL
Intervention: 1% testosterone solution applied to the axilla
Number of subjects: 0

Group type: COMPARATOR
Intervention: 1% testosterone solution applied to the inner arm
Number of subjects: 0
Study: 22804703

Group type: EXPERIMENTAL
Intervention: Word-based method
Number of subjects: 48

Group type: COMPARATOR
Intervention: Picture-based method
Number of subjects: 48
Study: 21178926

Group type: EXPERIMENTAL
Intervention: Low-frequency vibration exercise (LFT, 20 Hz, 0.4 mm)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: High-frequency vibration exercise (HFT, 36 Hz, 0.4 mm)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Non-vibration control (CON, 0 Hz, 0 mm)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: All treatments (CON, LFT, HFT)
Number of subjects: 20
Study: 17419744

Group type: EXPERIMENTAL
Intervention: Caspofungin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Liposomal amphotericin B
Number of subjects: 0
Study: 15744462

Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 12466506

Group type: EXPERIMENTAL
Intervention: Rhythm-control therapy
Number of subjects: 4060

Group type: COMPARATOR
Intervention: Rate-control therapy
Number of subjects: 4060
Study: 10329827

Group type: COMPARATOR
Intervention: Saline solution injections (placebo)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Injected allergens (active substances)
Number of subjects: 132
Study: 7552560

Group type: EXPERIMENTAL
Intervention: Continuous treatment teams
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard case management programs
Number of subjects: 0
Study: 2117202

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy (including recombinant t-PA and urokinase)
Number of subjects: 100000

Group type: EXPERIMENTAL
Intervention: Recombinant t-PA infusions
Number of subjects: 100000

Group type: EXPERIMENTAL
Intervention: Innovative administration regimens of urokinase
Number of subjects: 100000

Group type: COMPARATOR
Intervention: Thrombolytic therapy
Number of subjects: 100000
Study: 7388323

Group type: EXPERIMENTAL
Intervention: Low dose heparin (1000 units/1000 ml infusate) given intravenously
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Subcutaneous low dose heparin (5000 units 8-hourly)
Number of subjects: 108
Study: 30903598

Group type: EXPERIMENTAL
Intervention: Accepted participation in clinical trial
Number of subjects: 16

Group type: COMPARATOR
Intervention: Refused participation in clinical trial
Number of subjects: 16
Study: 31798841

Group type: EXPERIMENTAL
Intervention: Peer-identified change agents (PICAs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Management-selected change agents (MSCAs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Both PICAs and MSCAs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PICAs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MSCAs
Number of subjects: 0
Study: 27284082

Group type: EXPERIMENTAL
Intervention: Active dose of methylene blue (195 mg)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo (15 mg)
Number of subjects: 37
Study: 25858972

Group type: EXPERIMENTAL
Intervention: Stratified care training (n=67)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard care (n=33)
Number of subjects: 100
Study: 24352096

Group type: EXPERIMENTAL
Intervention: Multi-micronutrient supplement with nutritional doses of antioxidant nutrients and phytochemicals (MP) for eight weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo for eight weeks
Number of subjects: 80
Study: 21401336

Group type: EXPERIMENTAL
Intervention: Kinesio® tape (KT) and physiotherapy
Number of subjects: 31

Group type: COMPARATOR
Intervention: Physiotherapy only
Number of subjects: 31
Study: 19585317

Group type: EXPERIMENTAL
Intervention: 6 g L‐citrulline‐malate
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control
Number of subjects: 17
Study: 17453233

Group type: EXPERIMENTAL
Intervention: Squeezing a rubber ring at 30% of Maximal Voluntary Contraction (MVC) for 6 weeks
Number of subjects: 14
Study: 11000589

Group type: EXPERIMENTAL
Intervention: Group 1 (patients with left ventricular thrombus)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Group 2 (patients without left ventricular thrombus)
Number of subjects: 80
Study: 8638790

Group type: EXPERIMENTAL
Intervention: Oral clonidine (5 micrograms/kg)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control (no clonidine)
Number of subjects: 26
Study: 1992957

Group type: EXPERIMENTAL
Intervention: Filicol (9 g/d)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Gemfibrozil (1.2 g/d)
Number of subjects: 50
Study: 6391497

Group type: EXPERIMENTAL
Intervention: pizotifen 1 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: pirenzepine 50 mg
Number of subjects: 6

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 6
Study: 30851515

Group type: EXPERIMENTAL
Intervention: MTX + SIN (Methotrexate + Sinomenine) at a dose of 120 mg twice daily
Number of subjects: 120

Group type: COMPARATOR
Intervention: MTX + LEF (Methotrexate + Leflunomide) at a dose of 20 mg once daily
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: MTX + SIN
Number of subjects: 120

Group type: COMPARATOR
Intervention: MTX + LEF
Number of subjects: 120
Study: 30890061

Group type: EXPERIMENTAL
Intervention: Continue ART after delivery
Number of subjects: 1611

Group type: COMPARATOR
Intervention: Discontinue ART after delivery
Number of subjects: 1611